Are there particular subsets of AAV patients in which avacopan is more effective?

The following answer was jointly drafted by Dr. Peter Merkel and Dr. David Jayne:

Patients in the ADVOCATE trial were stratified at entry according to time of diagnosis (new/relapsing), diagnosis (GPA/MPA), ANCA serotype (PR3/MPO), and background immunosuppressive (cyclophosphamide/rituximab) with re...